Cargando…

Recent findings in the regulation of G6PD and its role in diseases

Glucose-6-phosphate dehydrogenase (G6PD) is the only rate-limiting enzyme in the pentose phosphate pathway (PPP). Rapidly proliferating cells require metabolites from PPP to synthesize ribonucleotides and maintain intracellular redox homeostasis. G6PD expression can be abnormally elevated in a varie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meng, Qingfei, Zhang, Yanghe, Hao, Shiming, Sun, Huihui, Liu, Bin, Zhou, Honglan, Wang, Yishu, Xu, Zhi-Xiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448902/ https://www.ncbi.nlm.nih.gov/pubmed/36091812 http://dx.doi.org/10.3389/fphar.2022.932154

Ejemplares similares

LKB1 deficiency-induced metabolic reprogramming in tumorigenesis and non-neoplastic diseases
por: Zhang, Yanghe, et al.
Publicado: (2020)

Key events in cancer: Dysregulation of SREBPs
por: Li, Yunkuo, et al.
Publicado: (2023)

The role of liver kinase B1 in tumor progression through regulation of lipid metabolism
por: Geng, Jialu, et al.
Publicado: (2022)

Lipid and glucose metabolism in senescence
por: Liu, Bin, et al.
Publicado: (2023)

Fenofibrate Improved Interstitial Fibrosis of Renal Allograft through Inhibited Epithelial-Mesenchymal Transition Induced by Oxidative Stress
por: Wang, Yishu, et al.
Publicado: (2019)

G6PD Variants and Haemolytic Sensitivity to Primaquine and Other Drugs
por: Bancone, Germana, et al.
Publicado: (2021)

The connection between tricarboxylic acid cycle enzyme mutations and pseudohypoxic signaling in pheochromocytoma and paraganglioma
por: Wang, Yuxiong, et al.
Publicado: (2023)

Genetic Variation of G6PD and CYP2D6: Clinical Implications on the Use of Primaquine for Elimination of Plasmodium vivax
por: Stewart, Alexandra G. A., et al.
Publicado: (2021)

Targeted changes in blood lipids improves fibrosis in renal allografts
por: Zhang, Yang-He, et al.
Publicado: (2023)

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
por: Shen, Xiangfeng, et al.
Publicado: (2019)

Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis
por: Xiang, Ze, et al.
Publicado: (2022)

Edible Bird’s Nest: Recent Updates and Industry Insights Based On Laboratory Findings
por: Chok, Kian Chung, et al.
Publicado: (2021)

Plants’ bioactive secondary metabolites in the management of sepsis: Recent findings on their mechanism of action
por: Mahomoodally, Mohamad Fawzi, et al.
Publicado: (2022)

Editorial: Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies
por: Wang, Yiting, et al.
Publicado: (2020)

Cellular Senescence in Adrenocortical Biology and Its Disorders
por: Gao, Xin, et al.
Publicado: (2021)

Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
por: Feng, Yuqian, et al.
Publicado: (2021)

Editorial: Targeting the PD-1/PD-L1 cancer immune evasion axis: Challenges and emerging strategies, Volume II
por: He, Xiujing, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism
por: Dong, Hao, et al.
Publicado: (2022)

A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
por: Mores, Kendall L., et al.
Publicado: (2019)

Recent Advances in Chitosan and its Derivatives in Cancer Treatment
por: Ding, Jingxian, et al.
Publicado: (2022)

Focusing on Formononetin: Recent Perspectives for its Neuroprotective Potentials
por: Tian, Jiao, et al.
Publicado: (2022)

Recent Advance of Nanomaterial-Mediated Tumor Therapies in the Past Five Years
por: Hao, Xinyan, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
por: Wang, Peng-Fei, et al.
Publicado: (2017)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 Inhibitors
por: Chen, Li, et al.
Publicado: (2022)

Allosterism vs. Orthosterism: Recent Findings and Future Perspectives on A(2B) AR Physio-Pathological Implications
por: Barresi, Elisabetta, et al.
Publicado: (2021)

The potential of targeting microRNA-23b-3p signaling in Alzheimer’s disease: opinions on recent findings
por: Wang, Chenyu, et al.
Publicado: (2023)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
por: Zhang, Ke, et al.
Publicado: (2022)

Recent Progress in CFTR Interactome Mapping and Its Importance for Cystic Fibrosis
por: Lim, Sang Hyun, et al.
Publicado: (2018)

The influence of pharmaceutical care in patients with advanced non-small-cell lung cancer receiving combination cytotoxic chemotherapy and PD-1/PD-L1 inhibitors
por: Kou, Wen, et al.
Publicado: (2022)

Controlling Nutritional Status (CONUT) Predicts Survival in Gastric Cancer Patients With Immune Checkpoint Inhibitor (PD-1/PD-L1) Outcomes
por: Chen, Li, et al.
Publicado: (2022)

Editorial: Recent Advances in G Protein-Coupled Receptor Signalling: Impact of Intracellular Location, Environment and Biased Agonism
por: Halls, Michelle L., et al.
Publicado: (2021)

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
por: Zhang, Jian-ye, et al.
Publicado: (2020)

Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
por: Singh, Vishakha, et al.
Publicado: (2021)

Corrigendum: Controlling nutritional status (CONUT) predicts survival in gastric cancer patients with immune checkpoint inhibitor (PD-1/PD-L1) outcomes
por: Chen, Li, et al.
Publicado: (2022)

6-Gingerol Regulates Hepatic Cholesterol Metabolism by Up-regulation of LDLR and Cholesterol Efflux-Related Genes in HepG2 Cells
por: Li, Xiao, et al.
Publicado: (2018)

Regulation of IFN-γ-mediated PD-L1 expression by MYC in colorectal cancer with wild-type KRAS and TP53 and its clinical implications
por: Guo, Libin, et al.
Publicado: (2022)

Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers
por: Ou, Shun-Long, et al.
Publicado: (2023)

Recent Developments in Pharmacological Effect, Mechanism and Application Prospect of Diazeniumdiolates
por: Li, Bin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s4torefsaipgu6r1fhj1jgaq9b